Tuesday, June 18, 2024

Psoriasis Treatment Breakthrough: Evaluating Deucravacitinib’s Cost-Effectiveness and Efficacy in Japan

Similar articles

A recent evaluation report from the National Institute of Public Health’s Center for Outcomes Research and Economic Evaluation for Health (C2H) provides new insights into the cost-effectiveness and clinical utility of Deucravacitinib (Sotyktu) for treating certain types of psoriasis. This comes as the drug received pricing approval in November 2022, with a current listed price of 2,770.90 yen as of April 2024.

The report focused on assessing Deucravacitinib’s effectiveness for patients with plaque psoriasis, pustular psoriasis, and psoriatic erythroderma, specifically those who have not sufficiently responded to existing treatments. The study used a rigorous framework, including comparisons with cheaper alternatives such as ixekizumab, risankizumab, bimekizumab, and apremilast.

Key findings from the report include:

  • The report concluded that Deucravacitinib does not offer additional benefits over Risankizumab for patients who have used biologic therapies after systemic treatment, as it showed inferior performance in achieving the Psoriasis Area and Severity Index (PASI).
  • For patients with no history of systemic therapy, Deucravacitinib showed statistically significant higher effectiveness compared to Apremilast in achieving PASI 75 scores, indicating a notable benefit in this group.
  • The cost-effectiveness analysis was conducted using a Markov model, factoring in various health states such as induction, maintenance, best supportive care, and death. Despite the mixed results in different patient groups, the study found that Deucravacitinib presented an Incremental Cost-Effectiveness Ratio (ICER) of 6,045,505 yen per Quality Adjusted Life Year (QALY) when compared to Apremilast, highlighting its economic value for patients without previous systemic therapy.


Psoriasis Care in Japan: C2H Report Sheds Light on Deucravacitinib’s Role

The release of this report by C2H is a significant development in the management of psoriasis in Japan. While the drug shows promise for certain groups, its overall benefit across all targeted conditions and patient profiles is mixed. This detailed evaluation will aid healthcare providers in making informed decisions about prescribing Deucravacitinib, especially considering the economic implications in the Japanese healthcare system.

The findings suggest a nuanced approach to treatment, where Deucravacitinib could be more suitable for specific segments of the patient population. This stratification could lead to more personalized psoriasis management strategies, aligning treatment options more closely with individual patient needs and previous treatment histories.

As the healthcare landscape continues to evolve with new treatments, such analyses are crucial for balancing clinical benefits with cost, ensuring that all patients receive effective, financially sustainable care. The government and healthcare providers will need to consider these factors when designing policies and treatment guidelines that maximize patient outcomes while managing the economic impact on the healthcare system.

Resource: National Institute of Public Health, April 28, 2024

You can follow our news on our Telegram and LinkedIn accounts.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article